Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seth B Coffelt

Showing results (31-40 of 68) with videos related to

Pageof 7
Sort By:
The American Journal of Pathology|February 20, 2010
Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumorsSeth B Coffelt, Claire E Lewis, Luigi Naldini, et al.
Plos One|December 9, 2017
PyMT-Maclow: A novel, inducible, murine model for determining the role of CD68 positive cells in breast tumor developmentRobin M H Rumney, Seth B Coffelt, Terence A Neale, et al.
Stem Cells (Dayton, Ohio)|October 6, 2007
Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responsesSuzanne L Tomchuck, Kevin J Zwezdaryk, Seth B Coffelt, et al.
European Journal of Immunology|September 20, 2025
Partial Compensation of IL-17 Production by Vγ1 T Cells in the Absence of Vγ4 and Vγ6 T CellsZiqing Wang, Tao Yang, Federico Lupo, et al.
Pain|March 4, 2015
Morphine does not facilitate breast cancer progression in two preclinical mouse models for human invasive lobular and HER2⁺ breast cancerChris W Doornebal, Kim Vrijland, Cheei-Sing Hau, et al.
Molecular Oncology|June 3, 2020
The MSP-RON axis stimulates cancer cell growth in models of triple negative breast cancerRhona Millar, Anna Kilbey, Sarah-Jane Remak, et al.
Oncotarget|September 9, 2017
Macrophages promote the progression of premalignant mammary lesions to invasive cancerEmily C Carron, Samuel Homra, Jillian Rosenberg, et al.
Experimental Hematology|March 24, 2007
Erythropoietin, a hypoxia-regulated factor, elicits a pro-angiogenic program in human mesenchymal stem cellsKevin J Zwezdaryk, Seth B Coffelt, Yanira G Figueroa, et al.
International Journal of Cancer|June 4, 2010
Emerging roles of the host defense peptide LL-37 in human cancer and its potential therapeutic applicationsWilliam K K Wu, Guangshun Wang, Seth B Coffelt, et al.
The Journal of Clinical Investigation|April 15, 2011
TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in miceAbigail F Welford, Daniela Biziato, Seth B Coffelt, et al.
Pageof 7

Showing results (31-40 of 68) with videos related to

Sort By:
Pageof 7
The American Journal of Pathology|February 20, 2010
Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumorsSeth B Coffelt, Claire E Lewis, Luigi Naldini, et al.
Plos One|December 9, 2017
PyMT-Maclow: A novel, inducible, murine model for determining the role of CD68 positive cells in breast tumor developmentRobin M H Rumney, Seth B Coffelt, Terence A Neale, et al.
Stem Cells (Dayton, Ohio)|October 6, 2007
Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responsesSuzanne L Tomchuck, Kevin J Zwezdaryk, Seth B Coffelt, et al.
European Journal of Immunology|September 20, 2025
Partial Compensation of IL-17 Production by Vγ1 T Cells in the Absence of Vγ4 and Vγ6 T CellsZiqing Wang, Tao Yang, Federico Lupo, et al.
Pain|March 4, 2015
Morphine does not facilitate breast cancer progression in two preclinical mouse models for human invasive lobular and HER2⁺ breast cancerChris W Doornebal, Kim Vrijland, Cheei-Sing Hau, et al.
Molecular Oncology|June 3, 2020
The MSP-RON axis stimulates cancer cell growth in models of triple negative breast cancerRhona Millar, Anna Kilbey, Sarah-Jane Remak, et al.
Oncotarget|September 9, 2017
Macrophages promote the progression of premalignant mammary lesions to invasive cancerEmily C Carron, Samuel Homra, Jillian Rosenberg, et al.
Experimental Hematology|March 24, 2007
Erythropoietin, a hypoxia-regulated factor, elicits a pro-angiogenic program in human mesenchymal stem cellsKevin J Zwezdaryk, Seth B Coffelt, Yanira G Figueroa, et al.
International Journal of Cancer|June 4, 2010
Emerging roles of the host defense peptide LL-37 in human cancer and its potential therapeutic applicationsWilliam K K Wu, Guangshun Wang, Seth B Coffelt, et al.
The Journal of Clinical Investigation|April 15, 2011
TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in miceAbigail F Welford, Daniela Biziato, Seth B Coffelt, et al.
Pageof 7